Managing Biopharma R&D Pipelines in an Era of Scientific Innovation
Rise of AI ML-Powered Accelerators in Pharma Secure Supply Chain
How New Oligonucleotide Modalities Are Reshaping Preclinical Development
Navigating the U.S. CDMO Industry
Antibody + Drug + Third Party, Antibody + siRNAASO + Third Party
EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoi...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
Strategic Alliances and Business Partnerships Across the U.S. Pharmaceutical Industry
US pharma partnerships are formal agreements in which two or more companies share the cost risk technology or market access involved in developing and selling a drug The most common forms are licensing deals codevelopment agreements cocommercialization arrangements and joint ventures Companies enter them because bringing a single drug
-
Techno Trends
Glycomine’s GLM101 Receives FDA Breakthrough Therapy Designation
Glycomine has received Breakthrough Therapy designation from the US Food and Drug Administration FDA for GLM an investigational treatment for phosphomannomutase congenital disorder of glycosylation PMMCDG a rare multisystem disorder with no approved therapies
-
Projects
Hovione Opens US$100 milllion East Windsor Pharma Manufacturing Expansion
Pharmaceutical CDMO Hovione has opened a new squarefoot facility at its East Windsor campus in New Jersey completing its current US million US investment programme The expansion doubles Hoviones US spraydrying capacity and strengthens its pharmaceutical development
-
Research Insights
Synthesis and evaluation of haemocompatible, antioxidant, and antibacterial properties, and acute oral toxicity of a methacrylic acid mediated glucoxylan for wound healing applications
Herein a copolymeric hydrogel comprising a naturally occurring swellable biopolymer ie glucoxylan a major polysaccharide of chia seed mucilage CM and methacrylic acid MA was synthesized through free
-
White Papers
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys complexity
TOP ARTICLES
-
1
Telehealth Revolution: Adapting Pharma Distribution Strategies for the Future
Kate Williamson
The article explores the transformative impact of telehealth on pharmaceutical distribution strategies. It delves into challenges such as logistics and regulatory compliance, presenting opportunities...
-
2
Latest Innovations Driving Progress in CNS Drug Development
Kate Williamson
This article explores recent innovations in CNS drug development, highlighting advancements in drug delivery systems, neuroimaging techniques, and the application of artificial intelligence. It discus...
-
3
The Role of CROs and CMOs in Accelerating Pharmaceutical Growth
Kate Williamson
Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) are very vital in the progress of the pharmaceutical business. Thus, being able to present their own research, cl...
-
4
The Influence of Big Pharma on Healthcare Policies in America: Unraveling the Complex Web
Kate Williamson
This article explores the intricate relationship between Big Pharma and healthcare policies in the United States, unraveling the historical context, lobbying tactics, and policy impact. It delves into...
-
5
Future of Pharma IT Infrastructure: Building Agile, Secure, and Data-Driven Enterprises
Lakshmi
American pharmaceutical companies are discovering that IT infrastructure sets the ceiling on everything else: how fast a product scales, how quickly quality issues surface, how far AI can be trusted....
press releasesRead more...
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
Genentech a member of the Roche Group SIX RO ROP OTCQX RHHBY announced today that the US Food and Drug Administration FDA has accepted the companys New Drug Application NDA
MedImpact Launches Claria™, a Distinctively New Approach to Delivering Pharmac Benefits
MedImpact the nations largest independent pharmacy benefit and health solutions company today introduced Claria an industryfirst approach that transforms PBM economics by giving plan
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
Codexis Inc NASDAQ CDXS a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing today announced an agreement with a pioneering siRNA drug innovator
Lifecore Biomedical to be Acquired by Webster Equity Partners
Lifecore Biomedical Inc Nasdaq LFCR today announced that it has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to million assuming full achievement
Events Read more...
28 - 02
Sep 2026Discovery on Target 2026
Boston, MA, USA
29 - 01
Sep 202610th IPF Summit 2026
Boston, MA, USA
29 - 01
Sep 2026Powtech Technopharm 2026
Nuremberg, Germany
30 - 01
Sep 2026Pharma Launch Excellence Summit
Hyatt Regency Boston Harbor, B...
05 - 06
Oct 2026ISPSAI France 2026
Paris, France
05 - 08
Oct 202616th World CB & CDx Summit 2026
Boston, MA, USA
12 - 14
Oct 2026Pharmaceutics 2026
Village Hotel Changi, Singapor...
12 - 13
Oct 20262nd International Conference on Drug Discovery
Village Hotel Changi, Singapor...
LATEST NEWSRead more...
AbbVie Partners with Valkai to Expand AI Use in Clinical Development
AbbVie has partnered with Valkai a life sciences artificial intelligence AI platform to expand the use of AI across selected areas of clinical development
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
Lifecore Biomedical has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to million subject to the achievement of certain performance milestones
Meitheal Pharmaceuticals Announces FDA Approval of High-Concentration Formulation of YUSIMRY®, a Biosimilar to Humira®
Meitheal Pharmaceuticals has announced that the US Food and Drug Administration FDA has approved a highconcentration formulation of YUSIMRY adalimumabaqvh an interchangeable biosimilar to Humira
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
Merck known as MSD outside of the United States and Canada and SciBrunch Therapeutics Co Ltd SciBrunch today announced that they have entered into an exclusive global license agreement for SPR an investigational preclinical oral KRAS GD ON inhibitor
FDA Grants Breakthrough Therapy Designation to Glycomine’s GLM101 for PMM2-CDG
The US Food and Drug Administration FDA has granted Breakthrough Therapy designation to Glycomines investigational GLM for the treatment of phosphomannomutase congenital disorder of glycosylation PMMCDG
Elevar Therapeutics Announces FDA Approval of Lyrfigtu for FGFR2-Altered Cholangiocarcinoma
Elevar Therapeutics has announced that the US Food and Drug Administration FDA has approved LYRFIGTU lirafugratinib as a treatment option for patients with cholangiocarcinoma CCA with an FGFR fusion or other rearrangement
